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LMTK3 is an oncogenic receptor tyrosine kinase
(RTK) implicated in various types of cancer, including
breast, lung, gastric, and colorectal cancer. It is local-
ized indifferent cellular compartments, but its nuclear
functionhasnotbeen investigatedso far.Wemapped
LMTK3 binding across the genome using ChIP-seq
and found that LMTK3 binding events are corre-
lated with repressive chromatin markers. We further
identified KRAB-associated protein 1 (KAP1) as a
binding partner of LMTK3. The LMTK3/KAP1 interac-
tion is stabilized by PP1a, which suppresses KAP1
phosphorylation specifically at LMTK3-associated
chromatin regions, inducing chromatin condensation
and resulting in transcriptional repression of LMTK3-
bound tumor suppressor-like genes. Furthermore,
LMTK3 functions at distal regions in tethering the
chromatin to the nuclear periphery, resulting in
H3K9me3 modification and gene silencing. In sum-
mary, we propose a model where a scaffolding func-
tion of nuclear LMTK3 promotes cancer progression
through chromatin remodeling.INTRODUCTION
Lemur tyrosine kinase 3 (LMTK3), a member of the receptor tyro-
sine kinase family (RTK), has been identified previously as an es-
trogen receptor a (ERa) regulator (Giamas et al., 2011) implicated
in endocrine resistance in breast cancer (Stebbing et al., 2013).
However, LMTK3 is expressed in both ERa+ and ERa breast
cancers, suggesting that it plays different cellular roles indepen-
dent of ERa status. Our recent work has revealed that elevated
cytoplasmic LMTK3 abundance in triple-negative breast cancer
promotes tumor invasion and metastasis (Xu et al., 2014), which
provided an example of the ERa-independent action of LMTK3.
Interestingly, both nuclear and cytoplasmic expression of
LMTK3 are correlated with tumor grade and patient survival
(Stebbing et al., 2012). However, the exact function of the
nuclear LMTK3 has not been determined so far.Several receptor tyrosine kinases (RTKs) havebeen reported to
localize in the nucleus, where they can regulate gene expression
(most likely transactivation) through binding to euchromatin
(Hung et al., 2008; Lin et al., 2001; Lo et al., 2005; Peng et al.,
2001; Wang et al., 2004). According to these reports, nuclear
RTKs are present in the nucleoplasm instead of the nuclear
lamina. In most cells, at least one class of heterochromatin is
positioned at the nuclear lamina, resulting in gene repression (An-
drulis et al., 1998; Finlan et al., 2008;Guelen et al., 2008; Kumaran
and Spector, 2008; Peric-Hupkes et al., 2010; Reddy et al., 2008;
Solovei et al., 2013; Towbin et al., 2012). Previous studies also
propose that heterochromatin relocation to the nuclear lamina
might occur via active tethering mediated by discrete molecular
complexes (Chubbet al., 2002;Poleshko et al., 2013). Theseperi-
nuclear heterochromatin hotspots are enriched with histone 3
lysine 9 dimethylation (H3K9me2) and trimethylation (H3K9me3)
modifications, which are usually associated with a number of
heterochromatin binding proteins such as KRAB-associated
protein 1 (KAP1/TIF1b/TRIM28), a binding partner of histone-
lysine N-methyltransferase SETDB1 (Grewal and Jia, 2007; Niel-
sen et al., 1999; Ryan et al., 1999; Zeng et al., 2010).
KAP1 is a transcriptional co-repressor whose activity is
regulated by post-translational modifications such as phosphor-
ylation and sumoylation. When phosphorylated, KAP1 affects
global chromatin decondensation (Ziv et al., 2006), which, in
turn, results in the derepression of KAP1-bound genes such as
those involved in cell-cycle arrest and apoptosis (Lee et al.,
2007; Li et al., 2007). It has been shown that KAP1 phosphoryla-
tion is regulated by protein phosphatases 1a (PP1a) and 1b
(PP1b), which are responsible for the maintenance of its repres-
sive function (Li et al., 2010).
In this study, we investigate the function of nuclear LMTK3
through mapping genome-wide chromatin interaction sites of
LMTK3 in breast cancer. We find that LMTK3 suppresses the
expression of tumor suppressor-like genes by tethering the
chromatin to the nuclear periphery, functioning as a catalytic
scaffold protein. Binding of LMTK3 to chromatin is mediated
via the interaction with PP1a and KAP1. The formation of this
complex leads to the suppression of KAP1 phosphorylation,
in turn strengthening this unique transcriptional repression
function. We show that a protein kinase has scaffolding prop-
erties, creating a system to enhance signaling complexity in
carcinogenesis.Cell Reports 12, 1–13, August 4, 2015 ª2015 The Authors 1
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Genome-wideMapping Identifies the LMTK3-Chromatin
Binding Profile
We have previously identified LMTK3 as a potential therapeutic
target in breast cancer that is expressed in ERa+ and ERa
breast cancer, whose expression carries prognostic signifi-
cance in both subgroups. As shown previously (Xu et al.,
2014), two specific LMTK3 bands are detected by western
blot analysis. We now demonstrate that LMTK3 localizes both
in the nucleus and in the cytoplasm of MCF7 and MDA-MB-
231 cells. The upper band is specifically localized in the cyto-
plasm, and the lower band is detected both in the cytoplasm
and in the nucleus, which suggests that the lower band is the
one that mainly functions in the nucleus (Figures S1A and
S1B). Because the importin protein family is known to mediate
macromolecules translocation from the cytoplasm to the nu-
cleus (Weis, 2003), we decided to investigate whether importins
are responsible for LMTK3 translocation by knocking down im-
portin a2 and importin b1 individually. We detected a notable
reduction in nuclear LMTK3 levels, with an increase in its cyto-
plasmic proportion after importin a2 but not importin b1 knock-
down (Figure S1C), suggesting that LMTK3 translocation is
mediated in an importin a2-dependent/importin b1-independent
manner, which has also been reported previously (Kotera et al.,
2005).
To decipher the function of LMTK3 in the nucleus, we mapped
the genome-wide profile of LMTK3-chromatin interactions by
chromatin immunoprecipitation sequencing (ChIP-seq) in the
ERa+/MCF7 and the ERa/MDA-MB-231 cell lines.We observed
3,086 loci in MCF7 and 24,516 loci in MDA-MB-231, in which
LMTK3 is located to the chromatin (Figures S1D and S1E).
Based on our previous work showing that LMTK3 interacts
with and phosphorylates ERa, which, in turn, promotes TFF1
expression (Giamas et al., 2011), we questioned whether
LMTK3-chromatin binding events are ERa-dependent. Interest-
ingly, we observed that LMTK3 binding in MCF7 (ERa+) and
MDA-MB-231 (ERa) have a high similarity (Figures 1A and
S1D) with a high correlation (R2 = 0.77) (Figure 1B). Supporting
the notion that chromatin-bound LMTK3 function may be inde-
pendent of ERa, we found no noticeable overlap and correlation
between LMTK3 and ERa binding (Figures S1F and S1G). More-
over, there were no significant changes in the enrichment of
selected LMTK3 binding genes in MCF7 cells upon fulvestrant-
mediated ERa degradation (Figure S1H), further suggesting
that the DNA binding events of LMTK3 are ERa-independent.
To further characterize the LMTK3 binding behavior, we then
tested the correlation of binding events of LMTK3 with two
groups of chromatin biomarkers (histone and transcription fac-
tors [TFs]): repressive promoter markers (histone 3 lysine 27 tri-
methylation [H3K27me3], H3K9me3, and SUZ12) and active
promoter or enhancer markers (histone 3 lysine 4 monomethyla-
tion [H3K4me1], histone H3 lysine 4 trimethylation [H3K4me3],
NANOG, p300, and TAF1). Interestingly, we found that LMTK3
binds chromatin at both repressive and active (Figures 1C, 1D,
and S1I) promoters, suggesting that there is a different binding
profile of LMTK3 compared with the ones of other known RTKs
(Lin et al., 2001; Wang et al., 2004).2 Cell Reports 12, 1–13, August 4, 2015 ª2015 The AuthorsNext, we validated LMTK3 bindings using ChIP-qPCR for
the most enriched LMTK3-binding genes. To confirm that the
bindings are LMTK3-specific, we constructed stable LMTK3
knockout (KO) MDA-MB-231 cells using a clustered regularly in-
terspaced short palindromic repeats (CRISPR)/CAS9 technique
by transfecting MDA-MB-231 cells with plasmids containing
hCAS9 and 2 guiding RNAs targeting exon 12 of LMTK3. Positive
clones showed a 112-base pair (bp) deletion (Figure S1J), and
clones with significant LMTK3 protein deletion were selected
(Figure S1K). Interestingly, we could not generate complete
LMTK3 KO MCF7 cells using the CRISPR technique. This may
be due to the fact that LMTK3 is so crucial for MCF7 cell growth
that LMTK3 KO cell clones stopped proliferating and could
not be selected. Therefore, we used our previously established
MCF7 cells stably overexpressing LMTK3 (MCF7-LMTK3). As a
result, LMTK3 binding events were notably higher in MCF7-
LMTK3 cells compared with MCF7 cells (Figure 1E) and were
barely detected in LMTK3-KO MDA-MB-231 cells (Figure 1F),
suggesting that the bindings detected are LMTK3-specific.
To investigate the binding event of LMTK3 in vivo, we injected
MCF7-LMTK3 cells subcutaneously into nude mice, harvested
the tumors, and performed LMTK3 ChIP. We discovered a
similar binding pattern of LMTK3 in the xenograft studies
compared with that in cell lines (Figure 1G). Finally, we also
confirmed LMTK3 bindings in both ERa+ and ERa breast can-
cer patient samples (Figure 1H). In summary, our results highlight
that nuclear LMTK3 is a chromatin-binding protein whose activ-
ity is independent of ERa status.
Motif and RIME Analyses Identify KAP1 as an
LMTK3-Associated Protein in Chromatin Binding
Similar to other RTKs, LMTK3 is unlikely to have a DNA-binding
domain. Therefore, binding of LMTK3 at DNA requires seq-
uence-specific transcription factors that interact with LMTK3.
A motif analysis provided a number of potential interacting
partners of LMTK3 (Figure 2A). We performed rapid immunopre-
cipitation mass spectrometry of endogenous proteins (RIME)
(Mohammed et al., 2013) to further address which of these can-
didates might be interacting partners of LMTK3 during DNA
binding and discovered 196 LMTK3-associated proteins (Fig-
ures 2B and S2; Table S1). Interestingly, KAP1 was enriched in
both analyses. We validated the interaction between LMTK3
and KAP1 by immunoprecipitation (Figure 2C). In addition, we
found a notable correlation between global LMTK3 and KAP1
binding events by comparing the ChIP-seq signals of LMTK3
and KAP1 (from the HEK293 cell line) (Figure 2D). We further
confirmed KAP1 as an LMTK3-binding partner by performing
KAP1 re-ChIP after LMTK3 ChIP (Figure 2E). In addition, we
also detected a similar binding profile of LMTK3 and KAP1 (Fig-
ure 2F). These data substantiate that KAP1 is an LMTK3 binding
partner in chromatin binding.
PP1a Stabilizes the LMTK3/KAP1 Interaction
and Mediates KAP1 Dephosphorylation at
LMTK3-KAP1-Bound Chromatin Regions, Resulting in
Chromatin Condensation and Gene Repression
We then investigated whether the LMTK3/KAP1 interaction is a
kinase-substrate process. No phosphorylation was observed
Figure 1. Identification of Genome-wide LMTK3 Binding Sequences with ChIP-Seq
(A) Binding of LMTK3 at the promoter of BAP1, GPAM, RBM42, and the distal interval in MCF7 and MDA-MB-231 cells.
(B) The correlation of LMTK3 binding signals in the MCF7 and MDA-MB-231 breast cancer cell lines.
(C) Clustering of genome-wide binding datasets with LMTK3. The color indicates similarity based on the Pearson correlation of the ChIP-seq peaks. The R2 values
of the correlation between LMTK3 bindings and SUZ12, H3K9me3, H3K27me3, H3K4me1, H3K4me3, NANOG, TAF1, and p300 binding are 0.53, 0.41, 0.48, 034,
0.4, 0.11, 0.26, and 0.27, respectively.
(D) H3K9me3 and H3K27me3 enrichment around LMTK3 peaks in MCF7 cells.
(E and F) ChIP-qPCR of LMTK3 bindings in MCF7 and MCF7-LMTK3 (E) and MDA-MB-231 and LMTK3 KO MDA-MB-231 cells (F).
(G) ChIP-qPCR of LMTK3 binding in an MCF7-LMTK3 cell-implanted xenograft.
(H) ChIP-qPCR of LMTK3 binding in human breast cancer tissues. Patient 1, ER+ PR+HER2; patient 2, ER+, HER; patient 3, ER+, PR+, HER; patient 4, ERPR
HER2+.
Quantitative data are presented as mean ± SD from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
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LMTK3 kinase domain (encompassing amino acids [aas] 149-
444) as a source of enzyme activity and glutathione S-trans-
ferase (GST)-KAP1 as a substrate (Figure S3A). On the contrary,
endogenous KAP1 phosphorylation at Ser824 was suppressed
after LMTK3 overexpression (Figures S3B and S3C). Because
PP1a is a known KAP1 phosphatase and a predicted LMTK3interaction partner (Hendrickx et al., 2009), we tested whether
PP1a is involved in the LMTK3/KAP1 interaction. Interestingly,
silencing of PP1a reduced the interaction between LMTK3 and
KAP1 (Figure 3A). We therefore generated GST-LMTK3 con-
structs and LMTK3 mutations at the PP1a docking motif
(PP1_RVxF) of LMTK3 (Figure 3B). As anticipated, a significant
decrease in LMTK3-PP1a binding was detected in both mutantsCell Reports 12, 1–13, August 4, 2015 ª2015 The Authors 3
Figure 2. KAP1 Is an Interacting Partner of LMTK3 in Chromatin Binding
(A) Selected examples of conserved TF motifs enriched within the interval regions associated with LMTK3.
(B) LMTK3 RIME in MCF7 cells identified potential LMTK3-associated proteins in DNA binding.
(C) Western blotting (WB) showing the immunoprecipitation (IP) of LMTK3 and KAP1 in MCF7 cells.
(D) KAP1 enrichment around LMTK3 peaks.
(E) qPCR results showing re-ChIP experiments using a KAP1 antibody after LMTK3 ChIP.
(F) Examples of LMTK3-KAP1 overlap based on snapshots of ChIP-seq data for the indicated genes.
See also Figure S2 and Table S1.
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the LMTK3/KAP1 interaction (Figures 3B and 3C). These results
suggest that PP1a is crucial for stabilizing the LMTK3-KAP1
complex.
KAP1 phosphorylation is critical in global chromatin decon-
densation (White et al., 2006; Ziv et al., 2006), leading to the
derepression of several basal KAP1-repressed genes (Lee
et al., 2007; Li et al., 2007). Therefore, we were interested in
elucidating the function of the LMTK3-PP1a-KAP1 interaction
on KAP1 phosphorylation status as well as its repressive func-
tion. Because basal levels of KAP1 phosphorylation are barely4 Cell Reports 12, 1–13, August 4, 2015 ª2015 The Authorsdetected, we used doxorubicin, a KAP1-Ser824 phosphorylation
inducer, as a molecular tool to study the LMTK3-PP1a-KAP1
effect on KAP1 phosphorylation. We further discovered that
silencing PPP1CA (a PP1a-encoding gene) rescued the reduced
Ser824 phosphorylation of KAP1 in MCF7-LMTK3 cells (Fig-
ure 3D), indicating that LMTK3 requires PP1a to dephosphory-
late KAP1. Silencing of PP1b, however, did not rescue the
reduced phosphorylation of KAP1 induced by LMTK3 (Fig-
ure S3D). Interestingly, we noticed that there was no increase
in KAP1 and PP1a interaction after LMTK3 overexpression
(Figure S3E), suggesting that LMTK3 might promote PP1a
Figure 3. PP1a Stabilizes the LMTK3/KAP1 Interaction and Suppresses KAP1 Phosphorylation on Ser824 at LMTK3-Binding Regions
(A) Immunoprecipitation of KAP1 and PP1a with LMTK3 in MCF7 cell lysates with and without PPP1CA silencing for 72 hr.
(B) Left: schematic of the PP1a-interacting motif (RVxF motif) on LMTK3 and the indicated GST constructs. Right: GST pull-down of PP1a using a wild-type
LMTK3 construct (GST-D10WT) and two RVxF motif mutants (GST-D10RVxF_1 and GST-D10RVxF_2). TM, transmembrane.
(C) FLAG immunoprecipitation performed after 24 hr of transient overexpression of FLAG-LMTK3WT and two mutants (FLAG-LMTK3RVxF_1 and FLAG-
LMTK3RVxF_2).
(D) Western blotting of the indicated proteins in MCF7 and MCF7-LMTK3 cells transfected with PPP1CA small interfering RNA (siRNA) for 72 hr and treated with
doxorubicin for 1 hr.
(legend continued on next page)
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We further questioned whether the reduced KAP1 phosphor-
ylation is predominantly observed at LMTK3-bound regions
and whether this would result in chromatin condensation. To
clarify this, we performed LMTK3 and KAP1 immunoprecipita-
tion using chromatin-bound MCF7-LMTK3 cell lysates. The ratio
of pKAP1/KAP1 in the LMTK3 immunoprecipitated chromatin
complex is significantly lower than that in the KAP1 immunopre-
cipitated chromatin complex (Figure 3E), suggesting that LMTK3
suppresses KAP1 phosphorylation specifically at LMTK3-bound
regions. Moreover, open chromatin is more enriched in MCF7
compared with MCF7-LMTK3 cells (Figure 3F), suggesting
that the region-specific dephosphorylation of KAP1 by LMTK3
could suppress chromatin decondensation. Then we tested
whether LMTK3/PP1a/KAP1-mediated chromatin condensation
can lead to gene silencing. Overexpression of wild-type (WT)
LMTK3, but not the mutant that abolishes its interaction with
PP1a and KAP1 (LMTK3RVxF_2), suppresses indicated gene
expression (Figure 3G) because of the fact that the latter lost
the DNA-binding activity at these regions (Figure 3H). In sum-
mary, these results demonstrate that an LMTK3-PP1a interac-
tion suppresses KAP1 phosphorylation, resulting in chromatin
condensation and transcriptional repression.
LMTK3 and KAP1 Suppress Gene Expression at Distal
Regions by Tethering Chromatin to the Nuclear
Periphery
To decipher the function of LMTK3 chromatin binding, we sepa-
rated LMTK3 and KAP1 binding events into promoter regions
that are 1 kb preceding the transcription starting site and the
rest as distal intervals. A recent study has suggested that
KAP1 is highly associated with H3K9me3-marked heterochro-
matin (Bartke et al., 2010), (Iyengar et al., 2011; Vogel et al.,
2006) and interacts with lamin A, a well characterized constituent
of the nuclear lamina (Roux et al., 2012) that is associated with
inactive chromatin regions (Kind et al., 2013; Peric-Hupkes
et al., 2010; Sadaie et al., 2013). Despite the function of
LMTK3 in chromatin condensation and transcriptional silencing,
we found that distal intervals bound by LMTK3 (or KAP1) are
associated with H3K9me3 modifications (Figure S4A). We there-
fore investigated the role of LMTK3 and KAP1 distal binding in
the context of transcriptional repression. We discovered, using
confocal microscopy, that LMTK3 (Figure 4A) and KAP1 (Fig-
ure S4B) co-localize with H3K9me3 both in the center and at
the inner nuclear membrane. Studies have shown that gene tran-
scription is suppressed when H3K9me3-marked heterochro-
matin is tethered to the nuclear periphery (Finlan et al., 2008;
Reddy et al., 2008; Towbin et al., 2012). Therefore, we investi-
gated whether LMTK3 and KAP1 are implicated in this process.(E) Immunoprecipitation of p-KAP1 (Ser824) and KAP1 with LMTK3 and KAP1 usi
associated) and KAP1-immunoprecipitated (Global) p-KAP1/KAP1 ratios are sho
(F) Formaldehyde-assisted isolation of regulatory elements (FAIRE)-qPCR in MC
(G) qPCR of LMTK3-bound gene expression in MCF7, MCF7-LMTK3WT, and MC
(H) FLAG ChIP-qPCR of LMTK3-bound chromatin regions in MCF7-LMTK3WT an
Quantitative data are presented as mean ± SEM from three experiments. Student
also Figure S3.
6 Cell Reports 12, 1–13, August 4, 2015 ª2015 The AuthorsWhen KAP1 was silenced, we noticed a partial loss of H3K9me3
staining on the inner nuclear membrane (Figure S4C). Similarly,
we found that overexpression of LMTK3 significantly increased
the proportion of H3K9me3 heterochromatin staining on the
periphery (Figure 4B) compared with control cells, whereas
LMTK3 deletion in MDA-MB-231 cells had the opposite effect
(Figure S4D), suggesting that LMTK3 and KAP1 are involved in
the heterochromatin repositioning process. To clarify whether
LMTK3 interacts with the nuclear lamina, we used a series of
GST-LMTK3 truncated protein constructs (Figure 4C) and per-
formed in vitro GST pull-down assays. Notably, part of the struc-
turally disordered domains of LMTK3 (D3 and D4) were found to
interact with lamin A (Figure 4C), suggesting that LMTK3 may
function as a scaffold protein inducing heterochromatin reposi-
tioning at the nuclear periphery by interactingwith Lamin A. Inter-
estingly, we also detected a significant overlap of LMTK3 distal
binding regions with lamin-associated domains (LADs) (Guelen
et al., 2008), supporting the hypothesis that LMTK3-associated
regions are located at and interact with the nuclear lamina
(Figure 4D). In aggregate, these results suggest that the
LMTK3-KAP1 complex appears to be involved in tethering
heterochromatin to the nuclear periphery.
To detect the sub-nuclear localization of the specific genomic
regions bound by LMTK3, we performed DNA fluorescence
in situ hybridization (FISH) with bacterial artificial chromosome
(BAC) probes mapped to genomic regions where LMTK3 bound.
We found an increase in FISH signals of the LMTK3-bound
region (RP11-54O14) detected at the nuclear periphery when
LMTK3 was overexpressed, whereas no significant change
was observed in the non-LMTK3-bound region (RP11-113M21)
(Figure 4E). The H3K9me3 signal was mostly increased upon
LMTK3 overexpression at these regions, presenting a significant
association with the increased FISH signals (Figure 4F).
To extend these observations and evaluate the transcriptional
effect of active localization of the LMTK3-bound regulatory
region to the nuclear periphery, we analyzed the expression pat-
terns of genes around LMTK3 distal binding regions with RNA
sequencing (RNA-seq) data. We chose the genes located near
the distal intervals bound by LMTK3 (potential nuclear lamina an-
chors) and separated them into three groups: less than 100 kb
(<100 kb) (18 genes), between 100 and 200 kb (100200 kb)
(14 genes), and between 200 and 500 kb (200500kb) (39 genes)
distance from LMTK3 binding sites (Figure 4G). We then
compared the expression levels of the groups according to their
expression values from RNA-seq. Notably, the expression levels
of genes that are more distant from LMTK3 binding sites
(100200 kb and 200500 kb) were relatively higher (Figure 4H).
Interestingly, we detected a limited number of genes near
LMTK3 distal binding sites. This can be explained by the fact
that LMTK3 binding regions are highly associated withng chromatin-bound MCF7-LMTK3 cell lysate (upper panel). LMTK3- (LMTK3-
wn (lower panel).
F7 and MCF7-LMTK3 cells at the indicated regions.
F7-LMTK3RVxF cells.
d MCF7-LMTK3RVxF (FLAG-tagged) cells.
’s t test was used for statistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. See
Figure 4. Distally Binding LMTK3 Tethers H3K9me3-Marked Heterochromatin to the Nuclear Periphery and Suppresses Nearby Gene
Expression
(A) Confocal staining of LMTK3 and H3K9me3 in MCF7 cells. DAPI, 40,6-diamidino-2-phenylindole.
(B) Confocal staining of H3K9me3 and Lamin A/C in MCF7 and MCF7-LMTK3 cells. H3K9me3 signals at the nuclear periphery were quantified.
(legend continued on next page)
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gions (Guelen et al., 2008; Meuleman et al., 2013; Peric-Hupkes
et al., 2010; Pickersgill et al., 2006). We also confirmed that
LMTK3 might suppress nearby gene expression by testing the
expression of certain genes near LMTK3distal regions (Figure 4I).
This implies that LMTK3 binding at distal regulatory regions
may be involved in suppressing nearby gene expression through
tethering the heterochromatin to the nuclear periphery.
LMTK3, PP1a, and KAP1 Are Co-expressed in Breast
Cancers and Collaborate in Suppressing the Expression
of Tumor Suppressor-like Genes
To examine the clinical implication of transcriptional repression
because of LMTK3 DNA binding, we chose the top LMTK3 and
KAP1 binding genes at the promoter intervals and the top genes
near the distal intervals and tested the clinical correlation of their
mean expression levels and relapse-free survivals (RFSs) in
breast cancer patients. A lower expression of genes bound
by LMTK3 at promoter intervals (Figure 5A) and genes near
LMTK3 bindings at the distal intervals (Figure 5B) were corre-
lated with poorer RFS, suggesting that LMTK3-bound genes
behave like tumor suppressor genes.
We also found that LMTK3 expression is negatively correlated
with the expression of several LMTK3-bound genes in breast
cancer patient samples (The Cancer Genome Atlas [TCGA]
database). As examples, the expression of LMTK3 is negatively
correlated with that of GPAM (Figure 5C) and RABGAP1L
(Figure 5D), which are LMTK3-bound genes at promoter and
distal intervals, respectively. This supports the hypothesis that
LMTK3 directly regulates the transcription of LMTK3-bound
genes in vivo as well as in our cell lines models.
In agreement with previous studies, LMTK3 is significantly
overexpressed in breast cancer (Figure 5E). Therefore, we
decided to investigate the clinical impact of the LMTK3 binding
partners KAP1 and PP1a. KAP1 and PPP1CA are significantly
overexpressed in breast tumors compared with normal tissues
(Figure 5E, S5A, and S5B). In addition, high expression of
KAP1 and PPP1CA is associated with worse patient RFS (Fig-
ures 5F and 5G) and overall survival (Figures S5C and S5D).
We also questionedwhether LMTK3,PPP1CA, andKAP1 co-ex-
press in breast cancer. Our analyses revealed a positive correla-
tion between the expression of LMTK3 and KAP1 (Figure 5H),
LMTK3 and PPP1CA (Figure 5I), as well as KAP1 and PPP1CA
(Figure 5J) but not LMTK3 and PPP1CB (Figure S5E) in patient
samples (TCGA). These suggest that LMTK3, PP1a, and KAP1
collaborate in breast cancer progression, leading to poorer(C) Mapping of LMTK3 directly interacting proteins to constructs of LMTK3 usin
derivatives incubated with whole MCF7 cell lysate and precipitated using a GST
(D) The overlap of DamID LADs and LMTK3. The p value was calculated using a
(E) Projections of confocal FISH images with a probe covering LMTK3 distal bind
RP11-54O14 and RP11-113M21 (non-LMTK3-bound region) are shown.
(F) The percentage of FISH signals at the nuclear periphery is plotted against the H
distal regions. RP11-113M21 was used as a negative control.
(G and H) Genes were divided into three groups based on their distance to the nea
RNA-seq analysis.
(I) qPCR of LMTK3 distally bound gene expression in MCF7 and MCF7-LMTK3W
Quantitative data are presented as mean ± SD. Student’s t test was used for sta
8 Cell Reports 12, 1–13, August 4, 2015 ª2015 The Authorssurvival rates by inhibiting a number of tumor suppressor-like
genes.
DNA-Binding Activity Is Crucial for LMTK3-Mediated
Tumor Growth In Vitro and In Vivo
We also investigated whether the previously described prolif-
eration advantage of LMTK3 in MCF7 cells (Xu et al., 2014) is
ERa-mediated. We observed that, upon ERa removal via fulves-
trant treatment, the proliferation of both MCF7 and MCF7-
LMTK3 cells was significantly suppressed. However, in the
absence of ERa, MCF7-LMTK3 cells could still proliferate faster
than MCF7 cells (Figure S6A). Moreover, knockout of LMTK3 in
the ERa MDA-MB-231 cells resulted in a slight but statistically
significant reduction in cell proliferation (Figure S6B). Taken
together, these results suggest that the involvement of LMTK3
in cell growth could partly depend on ERa but can also be sub-
ject to its transcriptional repression of tumor suppressor-like
genes through DNA binding.
We then examined, in vitro and in vivo, the tumor growth rates
of WT LMTK3 (MCF7-LMTK3WT) and LMTK3 mutant (MCF7-
LMTK3RVxF) cells that lost their DNA binding activity. MCF7-
LMTK3RVxF cells proliferated significantly slower compared
with MCF7-LMTK3WT cells (Figure 6A). Moreover, mice injected
with MCF7-LMTK3RVxF cells also developed smaller tumors
compared with WT cells (Figures 6B and 6C). These data indi-
cate that abolishing the DNA binding ability of LMTK3 on tumor
suppressor-like genes inhibits tumor progression.
In summary, we propose amodel in which nuclear LMTK3me-
diates chromatin remodeling by interacting with KAP1 and PP1a
(the latter dephosphorylates KAP1 at LMTK3-specific chromatin
binding regions, promoting chromatin condensation and tran-
scriptional repression) and tethering the chromatin to the nuclear
lamina through interaction with lamin A. These events result in
LMTK3 inducing transcriptional repression of its targeted tumor
suppressor-like genes and, thereby, supporting cancer cell sur-
vival and tumor growth (Figure 7).
DISCUSSION
We have previously demonstrated the role of cytoplasmic
LMTK3 in regulating integrin-associated metastatic potential
(Xu et al., 2014) and ERa transcriptional activity (Giamas et al.,
2011) in breast cancer. Here we describe a role of nuclear
LMTK3 and reveal that its chromatin binding and gene regulation
are mediated via its scaffold behavior. This is the first time that
an RTK has been ascribed such a role, lending credence tog a GST pull-down assay. Left: schematics of GST-tagged LMTK3 truncation
antibody. Right: immunoprecipitates tested by western blotting.
genomic association test (GAT) (Heger et al., 2013).
ing regions in MCF7 and MCF7-LMTK3 cells. FISH signals of the BAC clones
3K9me3 enrichments detected by H3K9me3 ChIP-qPCRwithin LMTK3-bound
rest distal intervals bound by LMTK3. Their expression levels were obtained by
T cells.
tistical analysis. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.
Figure 5. LMTK3, PP1a, and KAP1 Co-express in Breast Cancer and Collaborate in Suppressing the Expression of Tumor Suppressor-like
Genes
(A) Kaplan-Meier plots demonstrating the association of the mean expression profile of the available top 30 genes bound by LMTK3 at promoter intervals with
relapse-free survival (p = 5.1 3 1012) in 3,455 breast cancer patients. HR, hazard ratio.
(B) Kaplan-Meier plots demonstrating the association of the mean expression profile of the top ten genes near LMTK3 distal binding intervals with relapse-free
survival (p = 1.4 3 109) in 3,455 breast cancer patients.
(C and D) Correlation of the expression of LMTK3 and LMTK3 target genes in TCGA breast cancer datasets. The correlation of LMTK3 and GPAM (C) and
RABGAP1L (D) is shown as representatives of LMTK3-bound genes at the promoter and distal intervals, respectively.
(E) The expression profiles of LMTK3,KAP1, andPPP1CA in 63 normal breast tissues and 536 breast cancer tissues. Data are presented asmean ±SD. Student’s
t test was used for statistical analysis.
(F) Kaplan-Meier plots demonstrating the association between KAP1 expression and relapse-free survival (p = 6 3 104) in n = 3455 breast cancer patients.
(G) Kaplan-Meier plots demonstrating the association between PPP1CA expression and relapse free survival (p = 9.1 3 109) in 3,455 breast cancer patients.
(H–J) Correlation of the expression of LMTK3,KAP1, and PPP1CA in TCGA breast cancer datasets. LMTK3 and KAP1 (H), LMTK3 and PPP1CA (I), and KAP1 and
PPP1CA (J) are shown.
Kaplan-Meier plots were obtained from http://kmplot.com/. TCGA datasets were obtained from https://tcga-data.nci.nih.gov/tcga/. Correlation statistical
analysis was done using Pearson correlation test. See also Figure S5.
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Although scaffolding proteins are typically devoid of catalytic ac-
tivity, its presence here (by virtue of the fact that it is an active
RTK) is likely to have a far greater impact on signal processing
that anticipated by its kinase function alone. We propose thatthis dual function contributes to tumorigenesis by enhancing
signaling complexity.
Being an RTK, LMTK3 is unlikely to have a direct DNA binding
domain, suggesting the existence of other interacting part-
ners for its chromatin association. We discovered that theCell Reports 12, 1–13, August 4, 2015 ª2015 The Authors 9
Figure 6. DNA-Binding Activity Is Crucial for
LMTK3-Mediated Tumor Growth In Vitro
and In Vivo
(A) Sulforhodamine B (SRB) proliferation assay of
MCF7-LMTK3WT and MCF7-LMTK3RVxF cells.
(B) Xenografts of BALB/c nude mice subcutane-
ously injected with MCF7-LMTK3WT and MCF7-
LMTK3RVxF cells. Red boxes present the tumors
on day 28.
(C) Tumor volumes of xenografts of mice sub-
cutaneously injected with MCF7-LMTK3WT and
MCF7-LMTK3RVxF cells on day 14.
Quantitative data are presented as mean ± SD.
Student’s t test was used for statistical analysis.
***p < 0.001. See also Figure S6.
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little overlap between the binding genes of LMTK3 and ERa
was observed. In addition, ERa was not detected in the RIME
analysis. These results appear to be initially contradictory with
our previous finding describing LMTK3 as an ERa regulator (as
shown by modulating the transcription of TFF1, an ERa-regu-
lated gene) (Giamas et al., 2011). However, the binding of
LMTK3 and ERa to DNA is an independent procedure. The regu-
lation of ERa by LMTK3 is a transient phosphorylation process
that occurs in the cytoplasm, which results in activation of
ERa, translocation into the nucleus and binding to specific
DNA regions. The process by which LMTK3 itself translocates
to the nucleus and interacts with transcription factors (other
than ERa), which eventually leads to DNA binding is mediated
via other mechanisms, one of which is described here. There-
fore, the interaction of LMTK3 with ERa and its phosphorylation
at the cytoplasm does not necessarily mean that this complex
exists and acts together inside the nucleus and, subsequently,
binds to the chromatin.
Therefore, to identify potential partners of LMTK3 in chromatin
binding, a RIME assay was employed, and several proteins
involved in transcriptional repression were detected, many of
which were found to interact with silenced chromatin, and their
bindings were associated with enriched H3K9me3 signals
(Bartke et al., 2010). Interestingly, only LMTK3 bindings at distal
(enhancer) intervals were associated with H3K9me3 enrichment,
suggesting a distinct regulation of LMTK3 at promoter and
enhancer intervals.
Studies have shown that molecular tethering of H3K9me3-
marked heterochromatin to the nuclear periphery results in tran-
scriptional repression of genes located in these regions (Finlan
et al., 2008; Reddy et al., 2008; Towbin et al., 2012). Here we
demonstrate that LMTK3 functions as a scaffold protein linking10 Cell Reports 12, 1–13, August 4, 2015 ª2015 The Authorsheterochromatin to the nuclear lamina.
In addition, we show that the expression
levels of genes close to LMTK3-bound re-
gions are relatively lower, suggesting that
localization to the periphery suppresses
the expression of these genes.
Apart from its well defined kinase
domain, LMTK3 contains many intrinsi-
cally disordered regions (http://www.disprot.org/), which may participate in facilitating protein-protein
interactions implicated in a number of cellular processes (Kathir-
iya et al., 2014; van der Lee et al., 2014). We identified lamin A as
a direct interacting partner of LMTK3 that could be at least partly
responsible for the tethering process of heterochromatin to
the nuclear lamina, which results in chromatin remodeling and
H3K9me3 modification and subsequent tumor suppressor-like
gene repression. Our model (Figure 7) infers the assembly of
an LMTK3 ‘‘signalosome,’’ leading to dynamic regulation deter-
mined by overall module composition as opposed to individual
activity, with subsequent transcriptional effects.
On an evolutionary scale, recombination of catalytic and reg-
ulatory or scaffold domains could happen through exon shuf-
fling, and it is probable that a modular architecture is more
conducive for the rapid emergence of novel types of regulatory
mechanisms. Although it is very difficult to test this argument
experimentally, it is interesting to note that organism complexity
seems to correlate more with the number and diversity of regu-
latory domains and not with the number of integrated compo-
nents (such as catalytic domains) comprising a network (Bhatta-
charyya et al., 2006). LMTK3 lacks classical scaffolding domain
signatures (e.g., protein-protein interaction [PPI] domains such
as SH3 and PDZ), but, in common with other scaffolding pro-
teins, it binds signaling molecules both directly and indirectly.
Looking at the known examples of known scaffold proteins, it
seems that this group of signaling proteins is heterogeneous,
and it is unlikely that all scaffolds are linked through a common
ancestry. This is supported by the diverse, unrelated ways by
which scaffolds can come into existence (e.g., active compo-
nents turn into scaffolds or scaffolds that form by random asso-
ciations), and LMTK3 can therefore be categorized as a non-
classical, ‘‘randomly created’’ scaffold. The efforts within this
study, including genomic ChIP, are necessary to decipher these
Figure 7. Graphical Summary of Chro-
matin Remodeling and Transcriptional Co-
repressor Behavior of LMTK3
A schematic illustration ofmechanism of chromatin
remodeling mediated by nuclear LMTK3. LMTK3
binds PP1a through its C-terminal domains and
interacts with KAP1 and dephosphorylates KAP1
at Ser824, which results in chromatin condensa-
tion. Meanwhile, a part of the LMTK3 disordered
domain tethers the whole heterochromatin com-
plex to the nuclear lamina through interacting with
Lamin A. These result in the transcriptional
repression of LMTK3-bound tumor suppressor-like
genes.
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quences derived from sequenced genomes are compared, has
a very low chance to identify scaffolding interactions, and even
inferring binary connections between annotated gene products
is difficult.
Despite being bound to repressive promoters and enhancers,
LMTK3 is also able to bind to active promoters (Figure S1I) via
other proteins, among them CREB1. Our LMTK3 ChIP-seq
data revealed that the CREB1 motif is one of the most enriched
ones. In addition, CREB1 shares binding regions with LMTK3
at the promoters of PTPN11, PELP1, and RPS6KB2. LMTK3
overexpression promotes the expression of these genes, gener-
ally characterized as oncogenes, in breast cancer (Aceto et al.,
2012; Pe´rez-Tenorio et al., 2011; Rajhans et al., 2007; Roy
et al., 2012).
KAP1 has been shown to be overexpressed in a number of
cancers (Beer et al., 2002; Silva et al., 2006; Yokoe et al.,
2010). Here we demonstrate that, when co-expressed with
LMTK3, KAP1 functions as an oncogenic transcriptional co-
repressor through suppressing the expression of a number of
tumor suppressor-like genes (Figure 5). KAP1 phosphorylation,
especially at Ser824, has been shown to help chromatin decon-
densation and represents an inhibitory post-translational modifi-
cation for its co-repressive function (White et al., 2006; Ziv et al.,
2006); (Lee et al., 2007); (Li et al., 2007), and its phosphorylation
is known to be regulated by the protein phosphatase 1 family
members PP1a and PP1b (Li et al., 2010). In our work, we sug-
gest that LMTK3 specifically interacts with PP1a, which sup-
presses KAP1 phosphorylation at LMTK3-chromatin associated
regions, thereby maintaining the co-repressor function of this
complex. In addition, KAP1 phosphorylation is a DNA damage
marker (White et al., 2006; Ziv et al., 2006). Our results show
that KAP1 phosphorylation is suppressed during doxorubicin
treatment when LMTK3 is overexpressed, which suggests that
LMTK3 abundance might delay the induction of DNA damage
upon doxorubicin treatment. However, the contribution of
LMTK3 in this process requires further investigation, whichmight
further highlight its role in cancer cell survival.
Collectively, we demonstrate that LMTK3 functions as a tran-
scriptional co-repressor through interactingwith PP1a andKAP1
and as a scaffold protein by tethering heterochromatin to the nu-
clear lamina, resulting in chromatin remodeling and transcrip-
tional repression of LMTK3-bound tumor suppressor-like genes.The idea that an RTK could behave as a scaffold protein opens
up potential avenues for future research of these molecules.
EXPERIMENTAL PROCEDURES
Human Primary Tumor Samples
Institutional board approval was obtained for all work on tissue samples in
accordance with the Declaration of Helsinki.
Cell Culture and Generation of LMTK3 CRISPR Knockout Cells
Human breast cancer cell lines (MCF7 and MDA-MB-231) were purchased
from the American Type Culture Collection and were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS) and 1% penicillin and strepto-
mycin. Stable LMTK3-expressing MCF7 cells were generated and cultured
as described previously (Xu et al., 2014).
For experimental details for the generation of LMTK3 knockout cells, please
refer to the Supplemental Experimental Procedures.
ChIP-Seq Analysis
For experimental details, please refer to the Supplemental Experimental
Procedures.
Bioinformatic and Statistical Analyses
Peaks were called usingmodel-based analysis for ChIP-seq (MACS) under the
following recommended settings: bandwidth, 300; p value cutoff, 1 3 105;
mfold range, 10, 30. The false discovery rate (FDR) cutoff was 0.001 (0.1%)
for all peaks. Peaks and raw signals were then uploaded to and analyzed
with Galaxy and Cistrome.
RIME
RIME was performed as described previously (Mohammed et al., 2013) using
an LMTK3 antibody (Abnova, catalog no. H00114783-M02).
FISH
For experimental details, please refer to the Supplemental Experimental
Procedures.
Xenograft Mouse Models
BALB/c nude mice 7–8 weeks of age were purchased from Harlan Labora-
tories UK, and all procedures were carried out under Home Office license au-
thority and local ethics. MCF7-LMTK3WT and MCF7-LMTK3RVxF cells were
cultured in DMEM containing 10% FCS and 0.5 mg/ml of G418 and injected
subcutaneously into mice (seven mice/group) at a concentration of 5 3 106
cells/mouse. Tumor volumes were measured every 2 days using a caliper.
Public Data Sources
The following ChIP-seq peaks and raw signals were downloaded from the
Encyclopedia of DNA Elements (ENCODE): H3K9me3, H3K27me3, H3K27ac,
H3K4me1, H3K4me3, Pol2, TAF1, and P300 are generated from MCF7Cell Reports 12, 1–13, August 4, 2015 ª2015 The Authors 11
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Reports (2015), http://dx.doi.org/10.1016/j.celrep.2015.06.073cells; SUZ12 andNCOR are generated fromK562 cells; and KAP1 is generated
from HEK293 cells. ERa peaks and raw signals generated in MCF7 cells were
downloaded from a previous publication (Hurtado et al., 2008).
Patient survival data were acquired from http://www.kmplot.com.
Clinical correlation data were acquired from http://www.cbioportal.org and
http://www.canevolve.org.
Statistical Analysis
ChIP-seq analyses were done using Galaxy/Cistrome (http://cistrome.org).
Other data analyses were performed with Prism. Data are presented as
mean ± SD or SEM, as indicated in the figure legends.
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Figure S1, related to Figure 1. Genome-wide bindings of LMTK3 in MCF7 and MDA-MB-231 
cells are highly associated and ERα-independent. 
(A) Immunofluorescence staining of LMTK3 in MCF7 and MDA-MB-231 breast cancer cells.                      
(B, C) Western blotting of LMTK3 in cytoplasmic and nuclear cell fractions of MDA-MB-231 and 
MCF7 cells (B), and MDA-MB-231 cells transfected with Importin β1 and Importin α2 siRNAs for 72 
hr (C).	   (D) Heat map showing LMTK3 binding events in MCF7 and MDA-MB-231 cells.  (E) 
Distributions of LMTK3 binding events in MCF7. (F) Venn diagram presenting the overlap of LMTK3 
and ERα binding events in MCF7. (G) LMTK3 enrichments around ERα peaks in MCF7 cells. (H) 
LMTK3 ChIP-qPCR of MCF7 cells treated with 100nM fulvestrant or ethanol for 48 hr. Western blot 
for ERα was shown. (I) H3K4me2, H3K4me3, H3K27ac, Pol2, SUZ12 and NCOR enrichments 
around LMTK3 peaks. (J) Genomic DNA sequence of CRISPR targeting site in MDA-MB-231 LMTK3 
KO cell clones. 112bp deletion was detected. (K) Western blotting of selected clones. 
  
 
 
 
 
 
Figure S2, related to Figure 2. RIME validation. 
LMTK3 and its interacting proteins were precipitated using LMTK3 antibody, and then trypsinized 
overnight. Beads and trypsin solution were eluted with 2x laemmli buffer, and western blotting results 
were shown. 
 
 
 
 
 
 
 
 
 
 
 
Figure S3, related to Figure 3. LMTK3 suppresses KAP1 Ser824 phosphorylation through 
PP1α but not PP1β. 
(A) in vitro kinase assay testing LMTK3 kinase domain (KD) phosphorylation on KAP1 and positive 
control (B) Immunofluorescence staining of phosphor-KAP1 (S824) and LMTK3 in MCF7 and MCF7-
LMTK3 cells treated with doxorubicin for 1 hr. Quantification of relative phosphor-KAP1 intensity is 
shown. Student’s t test was used for statistical analysis. ***p < 0.001. (C) Western blotting of 
indicated proteins in MCF7-LMTK3 cells restored with LMTK3 siRNAs treated with doxorubicin for 1 
hr. (D) Western blotting of indicated proteins in MCF7 and MCF7-LMTK3 cells transfected with 
PPP1CB siRNA for 72 hr and treated with doxorubicin for 1 hr. (E) Immunoprecipitation of KAP1 with 
PP1α in MCF7 and MCF7-LMTK3 lysates. 
 
 
 
 
 
 
 
 
 
 
Figure S4, related to Figure 4. LMTK3 and KAP1 regulate the heterochromatin tethering 
process. 
(A) H3K9me3 signal profiles around the promoter (red) and the distal (black) intervals bound by 
LMTK3 (left panel) and KAP1 (right panel). (B) Confocal staining of KAP1 and H3K9me3 in MCF7. (C) 
Confocal staining of H3K9me3 and Lamin A/C in MCF7 cells with KAP1 silencing for 72 hr. H3K9me3 
signals at the nuclear periphery were quantified. (D) Confocal staining of H3K9me3 and Lamin A/C in 
MDA-MB-231 cells and LMTK3 KO MDA-MB-231 cells. H3K9me3 signals at the nuclear periphery 
were quantified. Student’s t test was used for statistical analysis. **p < 0.01, ***p < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure S5, related to Figure 5. PP1α and KAP1 are overexpressed in breast cancer and 
associated with poorer overall survival. 
(A, B) Heat maps of KAP1 (A) and PPP1CA (B) expressions in 43 paired normal and breast cancer 
tissues, obtained from http://canevolve.org based on GSE15852. (C, D) Kaplan-Meier plots 
demonstrating the association between KAP1 expression (C) and PPP1CA (D) and overall survival in 
n=1115 breast cancer patients. (E) Correlation of the expressions of LMTK3 and PPP1CB in TCGA 
breast cancer datasets. Correlation statistical analysis was done using the Pearson Correlation test. 
 
 
 
 
 
  
 
 
 
 
Figure S6, related to Figure 6. LMTK3 can stimulate cell proliferation without the presence of 
ERα. 
(A) Proliferation of MCF7 and MCF7-LMTK3 cells treated with 100nM fulvestrant or ethanol. 
Percentage reductions of cell viability of MCF7 and MCF7-LMTK3 cells after treating with fulvestrant 
were calculated.  (B) Proliferation of MDA-MB-231 and LMTK3 KO clones (KO-1 and KO-2) cells.  
 
 
 
 
 
 
 
 
 
 
 
Table S1, related to Figure 2. LMTK3-associated proteins on chromatin detected by RIME, 
Gene IDs are shown. 
AHNK DDX5 FXR1 HS90B NHRF1 RBM14 RS16 SYFA 
ALDOA DDX6 FXR2 HSP71 NONO RBM3 RS17L  TADBP 
ANXA2 DHX36 G3BP1 IF4A1 NOP16 RBM4 RS2 TBA1A  
ATX2 DHX9 G3BP2 IF4B NOP58 RBM47 RS24 TBB4B 
ATX2L DYHC1 G3P IF4G1 NP1L1 RBMX RS26 TCP4 
BAF EF1A2 GEMI5 IF4H NUCL RENT1 RS28 TCPZ 
CAPR1 EF1B GRSF1 ILF2 PABP1 RL11 RS3 THOC4 
CAZA1  EF1D H13 ILF3 PAIRB RL12 RS3A TIAR 
CBX3 EF1G H2A1B  IMA2 PATL1 RL18 RS6 TIF1B 
CC124 EF2 H2AY KHDR1 PCBP2 RL19 RS7 TKT 
CCDC9 EIF3A H2B1B  KPYM PDE3B RL23A RS8 TRI25 
CDV3 EIF3C H31T  LAP2A PGK1 RL27A RTCB UBP10 
CIRBP ELAV1 H4 LARP1 PLEC RL3 SERA UBP2L 
CLIC1 ENOA HMGB1 LARP4 PPIA RL38 SF3B2 WIBG 
CO3 ERF1 HNRH1 LMNA PRC2A RL4 SFPQ XRCC6 
COF1 ERF3A  HNRH3 LMNB1 PRDX1 RL6 SND1 YBOX2 
CPSF6 ESRP1 HNRL2 LRC47 PRDX2 RL7A SRC8 YTHD2 
CRIP2 F120A HNRPD LS14B PRDX6 ROA0 SRP14 YTHD3 
CSDE1 FAS HNRPF MATR3 PROF1 ROA1 SRRM2 ZC3H8 
DAZP1 FLNA HNRPK MBNL1 PSPC1 ROA2 SRSF2 ZN131 
DBPA FMR1 HNRPL MIF PTBP1 ROA3 SRSF3 ZN326 
DD19A  FUBP1 HNRPQ MK67I PUM1 ROAA SRSF6  
DDX1 FUBP2 HNRPR MOV10 PUR9 RRMJ3 SRSF9  
DDX17 FUBP3 HNRPU MYEF2 PURA RS10 STAU1  
DDX3X FUS HS90A NEDD8 RAN RS14 STAU2  
 
Table S2. Primers used in this study. 
 Gene names F’ R’ 
Genomic 
DNA 
BAP1 CCTCAGTCCCACACACAGAC GGAAGACGAGCCCAGAGG 
GLOD4 CTGCGAGCAGCCATGATT CGCCATGTTCCCTGAGAC 
GPAM AGTTCGCACCCTAGCAGCTC CGCACACTCGAGTACACACA 
RBM42 CTCATAGGCCCAGGTTCTTG CCGCTGGTTCTGCTGTCTAC 
TRMT61B AGGCACAGCAAGACAGGAC GGATGGTCACTCAACCAGGA 
CWC25 GAAATAGTTCGGGGGCTACC AGCCCTGTACGTCATCGTTC 
C1D GACTCCAGTCTCCCGGAAAG TGAGATTTGCCTTTGGAGAAG 
Distal-1 AAAGAGACAGCAGCCAGAGG GAGCACTACCTCGCACACTG 
Distal-2 TCCCTACGTGGGTAATCTGG CACAGCCACTGAGTGAAGGA 
Distal-3 GTTGTCTGGGATGTGCATTG ACACAGTGGGGTCACAGATG 
Negative ctl-1 GAGCAGCATTTTAGGCTTGG TGCAGTGGCTTTTCTCAATG 
Negative ctl-2 AAACCTGCACGCTGGACTAC CATGGCTGGCAAGAAGGT 
cDNA 
CWC25 ATTCCTCCCCTGTTTTGTCC GAAGACCCTGGTTACGGTCA 
GLOD4 AGATTCTGACTCCCCTGGTG GCTTCCCTCTGGATCCATCT 
GPAM CCAGCCTGTGCTACCTTCTC CTGTTTCATGGCAGACTTGG 
RBM42 CTGTGATCCGCCCAATTATC CCACCATGGGAGGAACTACT 
TRMT61B CCCAGGTGATACTGTTTTGGA GCCAGATCATGGTGGTCTTT 
TFPT CGGGAATTAAATCGCAGAAA CCGAGTTATCCTCTGCACCT 
RNFT2 CGAATGCCTACCTCCAGTGT TGGAATGTTATCCGTGTTGC 
C12orf49 GCTGCAGCGCCTATGAGTA CCAGGCACAACTCAAAGTGA 
HRK GGCCTTTCTTGTGCTTTTGA TCATACCCATCCTCCTCCAG 
RABGAP1L GGATCATCTGATTCTGTGGCTA CTCTTCCATGGCTTTTTCCA 
KIF5C CAGCAGGAGGTGGATCGTAT GAGATGAGGCCGGGTAGTGT 
PIP4K2A CAGTGGAGCTCGTTTTCACA GAAGAAGGGTGATCCCATGA 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Generation of LMTK3 CRISPR knockout cells 
MDA-MB-231 cells were transiently cotransfected with expression plasmids encoding the CRISPR 
guide RNA pairs (gRNA_1: GTGACCGTGAGCACATCGTC, gRNA_2: 
GGAAGGGACCGTCTCGGGGT) against LMTK3 exon 12, together with an expression plasmid 
encoding a CAS9-GFP fusion protein (Addgene), using lipofectamine LTX (Invitrogen, Carlsbad, CA). 
72 hr following transfection, cells were FACS sorted for GFP expression and re-plated at clonal 
densities to obtain single-cell clones. Genomic DNA from individual clones was used in PCR analysis 
of LMTK exon 12 and products indicating CRIPSR mediated deletion within the exon further 
characterized by DNA sequencing. Cell lysates prepared from LMTK3 exon 12 deletion positive 
clones were used in western blot analysis to confirm LMTK3 knockout. 
 
Chromatin immunoprecipitation (ChIP) and coupled to deep sequencing (ChIP-seq) analysis 
ChIP was performed with LMTK3 antibody (Abnova H00114783-M02). The sequences of primers 
used in ChIP-qPCR are listed in Supplemental Table S1. Negative control primers are targeting the 
chromatin regions that are not associated with LMTK3. 
For generating the ChIP-seq library, 5 ng of LMTK3 ChIP-enriched DNA was modified with the 
ChIP-seq DNA Sample Prep Kit (Illumina). The DNA end was ligated with adaptor (NEBNext® 
Multiplex Oligos for Illumina (Index Primers Set 1)), and PCR amplified for 15 rounds. Amplified DNA 
was gel purified through collecting the fragments around 300bp. The purified DNA was sent for 
sequencing (Illumina). Sequences were mapped to the human genome (hg19) using BOWTIE to 
yield unique alignments. Mapping rates are 90.24% and 88.38% for MCF7 and MDA-MB-231, 
respectively. 
 
 
Quantitative Real-time PCR 
RNA was harvested using RNeasy Kit (Qiagen) and 1µg of RNA was reverse-transcribed to cDNA 
(complementary DNA) using High Capagcity cDNA Reverse Transcription Kit (Applied Biosystems, 
Life Technologies). qRT-PCR was performed using SYBR Green assays (Applied Biosystems). For 
primers used in this study, BAP1 (QT00204701) and C1D (QT00041475) were purchased from 
Qiagen, the rest refer to Supplemental Table S2. 
 
Immunofluorescence 
MCF7 cells were seeded on coverslips and fixed for 15 min using 4% formaldehyde for 10 min, 
followed by incubation in 0.2% Triton X-100 for 10 min. Cells were then incubated with primary 
antibody (Mouse LMTK3 (Abnova H00114783-M02), 1:200; Mouse KAP1 (Abcam ab22553), 1:500; 
Rabbit Lamin A (Abcam ab2630), 1:1000; Mouse Lamin A/C (Santa Cruz sc-7292), 1:400; Rabbit 
H3K9me3 (Abcam ab8899), 1:500, Rabbit KAP1 (phospho S824) (Abcam ab70369), 1:1000) for 2 hr 
at room temperature. Subsequently, cells were washed with PBS and incubated with FITC 
(fluorescein isothiocyanate) or Texas Red–conjugated secondary antibodies for 1 hr each at room 
temperature. After being washed three times in PBS and air-dried, the coverslips were mounted in 
ProLong Gold anti-fade reagent with DAPI (Invitrogen, Carlsbad, CA). Fluorescence was detected 
using a Leica SP5 Confocal Microscope at appropriate wavelengths. 
 
Fluorescence In Situ Hybridization (FISH) 
MCF7 and MCF7-LMTK3 cell pellets were resuspended and incubated with hypotonic solution for 15 
min at 37°C, followed by 5 min centrifuging at 1300 rpm. Cells were fixed and a drop of the cells were 
placed on the slide, followed by 37°C incubation overnight. Slides were supplied with 150-200 µl of 
0.005% Pepsin/0.001 M HCl and incubated for 15 min at 37°C. Slides were incubated in PBS for 5 
min, post fixation washing buffer (10% PBS (10x), 10% MgCl2 0.5M in H2O) for 5 min, 
Paraformaldehyde (PFA) /PBS (10% PBS (10x), 10% MgCl2 0.5M, 30% H2O and 50% of 8% PFA) for 
5 min, PBS for 5min and 5 min each in ethanol series (70%, 90%, 100%). Slides were air-dried and 
supplied with the hybridization mix (1µl of indicated probes, 4.5 µl of pure formamide, 3.6 µl 25% 
Dextran Solfate and 0.9 µl of 20x SSC solution), followed by 5 min incubation at 75°C and 37°C 
overnight in dark. Slides were washed three times with 0.1x SSC for 5 min each at 57°C. Slides were 
supplied with DAPI and ready for analysis under the confocal microscope. 
 
Western blotting, immunoprecipitation and GST-pull-down assay. 
Cells were lysed in RIPA buffer (#R0278, SIGMA-ALDAICH) or co-IP buffer (for immunoprecipitation; 
50mM Tris pH 8.0, 150 mM NaCl, 0.5% Triton X- 100, 10% Glycerol, 1mM DTT) supplemented with 
protease and phosphatase inhibitors. Cell lysates were resolved by SDS–PAGE and immunoblotted 
with indicated antibodies. For immunoprecipitation, indicated antibodies (2  µg) were incubated with 
beads (ImmunoCruz™ IP/WB Optima Systems) for 2 hr at 4  °C, followed by three times wash with 
PBS. Beads and antibodies were then incubated with 1 mg of cell lysates at 4  °C overnight. 
Immunoprecipitates were washed three times with co-IP buffer before being resolved by SDS–PAGE 
and immunoblotted with indicated antibodies. For GST-pull-down assay, 20  µg GST-tagged proteins 
were incubated with GST beads 2 hr at 4  °C, followed by three times wash with PBS. 1mg cell lysates 
harvested by RIPA buffer were then incubated with beads at 4  °C overnight, followed by five times 
washing with PBS and then resolved by SDS–PAGE and immunoblotted with indicated antibodies. 
 
